This article relies largely or entirely on a
single source. (March 2024) |
Clinical data | |
---|---|
Drug class | Nonsteroidal androgen; Selective androgen receptor modulator |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C19H18F3N3O6 |
Molar mass | 441.363 g·mol−1 |
3D model ( JSmol) | |
| |
|
Acetoxolutamide is a nonsteroidal androgen and selective androgen receptor modulator (SARM) which was described in 2000 and was never developed or marketed for medical use. [1] It was derived from structural modification of the nonsteroidal antiandrogen bicalutamide and the nonsteroidal SARM acetothiolutamide. [1] Acetoxolutamide shows greatly improved pharmacokinetic properties and anabolic and androgenic potency relative to acetothiolutamide in animals. [1] It is the (2R) enantiomer of andarine (also known as acetamidoxolutamide or androxolutamide). [1]